NCIN prepares national, sub-national and cancer type specific analyses in collaboration with partner organisations.
We also prepare data briefings (short documents highlighting one issue and written for a wider general audience), cancer information tools targeted at particular audiences and guidance documents to support health service and other users in understanding and using the available information.
A range of other data on cancer in the UK are available from other organisations.
Most recent reports
This report examines trends in survival of kidney cancer, in England, over the most recent 20 years of data available 1990-2010. This report also endeavours to examine how one and five year survival rates of kidney cancer are influenced by sex, the histological cell type of the tumour, the grade of differentiation and the stage at presentation.
The first gynaecological cancer quality and completeness report was produced using the 2008 version of the NCDR, however, as the current NCDR has been compiled differently, it is important to assess the quality of the most recent data items and identify changes over time. As with the first report, the aim of this report is to assess the quality of key gynaecological cancer patient and tumour data items available in the NCDR, to allow an understanding of how the data may be used at UK level. This will provide a useful reference to those wanting to understand the scope of the NCDR in relation to gynaecological cancer specific projects, whilst also influencing improvements in the collection of gynaecological data, not only in the compilation of the NCDR, but also at the registration process level.
Rare urological cancers are defined here as cancer of the penis, testes, ureter & renal pelvis, plus bladder cancers of the non-transitional cell type and prostate cancer of the small cell type. Reports regarding these malignancies are uncommon, possibly due to their comparative rarity when compared with other malignancies.
This report attempts to address this imbalance and be a source of information for clinicians, commissioners, charitable bodies and those with an interest in this group of tumours.To determine whether the incidence, mortality and survival rates for the rarer tumours is actually changing, and whether there is variation over the time periods studied, the NCIN Urology SSCRG has commissioned a breakdown report on these rare urological cancers in England.
Pathology techniques are continually improving, resulting in the reclassification of tumours and the identification of new morphological types and sub-types. Over the last twenty years, many new types of sarcoma have been defined, including Ewing’s sarcoma and, more recently, gastro-intestinal stromal tumour (GIST). The 4th edition of the World Health Organisation (WHO) Classification of Tumours of Soft Tissue and Bone was published in 2012 and updates the classifications included in the 3rd edition which was published in 2002.
The Public Health England Knowledge and Intelligence Team (West Midlands) is the National Cancer Intelligence Network (NCIN) national lead analytical team for bone and soft tissue sarcomas. As such, it is important that any coding changes or additions in the 4th edition of the WHO classification are acknowledged and used in the analyses undertaken. This report compares the 3rd and 4th editions of “Tumours of Soft Tissue and Bone”, and discusses the implications of key changes on reported bone and soft tissue sarcoma incidence and survival rates.
This document aims to provide an overview about cancer statistics, including informationon the latest statistics publicly available and where to find them.This is intended to be a useful reference guide for infrequent users of cancer statistics orfor audiences that may not be familiar with this information. This document is structuredusing key chapters in the Improving Outcomes: a Strategy for Cancer.
This report presents the latest time trends, trends by age, and regional variations in incidence, mortality and survival for malignant uterine tumours in the UK. There is also a separate section on these cases stratified according to their main morphological groups. This report has been produced by Public Health England’s Knowledge and Intelligence Team (East Midlands) (formerly part of Trent Cancer Registry), the NCIN’s lead for gynaecological cancers, on behalf of the NCIN Gynaecological Site Specific Clinical Reference Group (SSCRG). These data should be of interest to all those involved in the commissioning and delivery of services to prevent, diagnose, and treat uterine cancer.
This report presents estimated completeness of ascertainment for childhood cancer in the UK, 2005-2010, the most recent period for which registration by the National Registry of Childhood Tumours (NRCT) has been declared complete. The most recent published estimates of completeness of ascertainment of childhood cancer in Britain by the NRCT cover years 2003-2004 1.
The purpose of this report is to assess whether NCRT is under reporting ascertainment of childhood cancers or not.
Primary bone and soft tissue sarcomas are an exceptionally rare form of cancer, collectively accounting for only 1% of all malignancies diagnosed. This report fills a void in publicly available data describing the incidence and survival of patients diagnosed with primary bone or soft tissue sarcoma in the UK. The report considers overall UK incidence and survival rates, and examines variations amongst the four UK countries. Differences between UK countries in the most common histologies and anatomical sites are also discussed.
Cytotoxic chemotherapy is used in the treatment of cancer to reduce the risks of disease recurrence following surgery (the adjuvant setting), and to prolong life and improve symptoms in those with metastatic disease (the palliative setting). Chemotherapy is associated with side-effects which include hair loss, lethargy, nausea, mucositis, diarrhoea, organ damage and risks of severe infection. It is difficult to predict which patients are likely to get side-effects, and the presence of co-morbidities and fitness plays a significant role in how cancer patients tolerate treatment. This therefore has an impact in the physicians’ choice/decision of chemotherapy usage and regimen for an individual patient. However there is no-one agreed gold standard method of using and measuring co-morbidity and fitness, and how this influences treatment. A recent survey of the NCIN site-specific clinical reference groups suggested that co-morbidities influenced decisions regarding chemotherapy across all tumour sites, and predicting chemotherapy toxicity has been highlighted as an area of critical importance by the National Chemotherapy Advisory Group report in 2009.
Reports from earlier in 2013
You can also see and download reports which we published before January 2013 on our reports archive page.